Publicação
Adjusting the brakes to adjust neuronal activity: adenosinergic modulation of GABAergic transmission
| dc.contributor.author | Sebastião, Ana M | |
| dc.contributor.author | Ribeiro, Joaquim A. | |
| dc.date.accessioned | 2023-05-30T13:18:38Z | |
| dc.date.available | 2023-05-30T13:18:38Z | |
| dc.date.issued | 2023 | |
| dc.description | © 2023 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) | pt_PT |
| dc.description.abstract | About 50 years elapsed from the publication of the first full paper on the neuromodulatory action of adenosine at a 'simple' synapse model, the neuromuscular junction (Ginsborg and Hirst, 1972). In that study adenosine was used as a tool to increase cyclic AMP and for the great surprise, it decreased rather than increased neurotransmitter release, and for a further surprise, its action was prevented by theophylline, at the time only known as inhibitor of phosphodiesterases. These intriguing observations opened the curiosity for immediate studies relating the action of adenine nucleotides, known to be released together with neurotransmitters, to that of adenosine (Ribeiro and Walker, 1973, 1975). Our understanding on the ways adenosine uses to modulate synapses, circuits, and brain activity, vastly expanded since then. However, except for A2A receptors, whose actions upon GABAergic neurons of the striatum are well known, most of the attention given to the neuromodulatory action of adenosine has been focusing upon excitatory synapses. Evidence is growing that GABAergic transmission is also a target for adenosinergic neuromodulation through A1 and A2A receptors. Some o these actions have specific time windows during brain development, and others are selective for specific GABAergic neurons. Both tonic and phasic GABAergic transmission can be affected, and either neurons or astrocytes can be targeted. In some cases, those effects result from a concerted action with other neuromodulators. Implications of these actions in the control of neuronal function/dysfunction will be the focus of this review. | pt_PT |
| dc.description.sponsorship | The authors research unit has been receiving support by European Union's Horizon 2020(H2020)-WIDESPREAD-05-2017-Twinning (EpiEpinet) under grant agreement No. 952455, and Fundação para a Ciência e a Tecnologia (FCT) (Projects number PTDC/MED-FAR/30933/2017 and PTDC/MED-FAR/4834/2021. | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.citation | Neuropharmacology. 2023 May 22;109600 | pt_PT |
| dc.identifier.doi | 10.1016/j.neuropharm.2023.109600 | pt_PT |
| dc.identifier.eissn | 1873-7064 | |
| dc.identifier.issn | 0028-3908 | |
| dc.identifier.uri | http://hdl.handle.net/10451/57688 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.publisher | Elsevier | pt_PT |
| dc.relation | Epileptogenesis and Epilepsy Network: from genes, synapses and circuits to pave the way for novel drugs and strategies | |
| dc.relation | In the search of the synaptic mechanism operated by a novel selective antiepileptic drug | |
| dc.relation | Does context matter for drug action? Contextual dependency of the long-lasting neurobiological and antidepressant actions of psilocybin | |
| dc.relation.publisherversion | https://www.sciencedirect.com/journal/neuropharmacology | pt_PT |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | pt_PT |
| dc.title | Adjusting the brakes to adjust neuronal activity: adenosinergic modulation of GABAergic transmission | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.awardTitle | Epileptogenesis and Epilepsy Network: from genes, synapses and circuits to pave the way for novel drugs and strategies | |
| oaire.awardTitle | In the search of the synaptic mechanism operated by a novel selective antiepileptic drug | |
| oaire.awardTitle | Does context matter for drug action? Contextual dependency of the long-lasting neurobiological and antidepressant actions of psilocybin | |
| oaire.awardURI | info:eu-repo/grantAgreement/EC/H2020/952455/EU | |
| oaire.awardURI | info:eu-repo/grantAgreement/FCT/3599-PPCDT/PTDC%2FMED-FAR%2F30933%2F2017/PT | |
| oaire.awardURI | info:eu-repo/grantAgreement/FCT/3599-PPCDT/PTDC%2FMED-FAR%2F4834%2F2021/PT | |
| oaire.citation.title | Neuropharmacology | pt_PT |
| oaire.citation.volume | 236 | pt_PT |
| oaire.fundingStream | H2020 | |
| oaire.fundingStream | 3599-PPCDT | |
| oaire.fundingStream | 3599-PPCDT | |
| person.familyName | Sebastião | |
| person.familyName | Ribeiro | |
| person.givenName | Ana M | |
| person.givenName | Joaquim | |
| person.identifier.ciencia-id | F112-55E8-E37E | |
| person.identifier.ciencia-id | 081F-2518-907F | |
| person.identifier.orcid | 0000-0001-9030-6115 | |
| person.identifier.orcid | 0000-0002-9330-3507 | |
| person.identifier.scopus-author-id | 7004409879 | |
| person.identifier.scopus-author-id | 35498669400 | |
| project.funder.identifier | http://doi.org/10.13039/501100008530 | |
| project.funder.identifier | http://doi.org/10.13039/501100001871 | |
| project.funder.identifier | http://doi.org/10.13039/501100001871 | |
| project.funder.name | European Commission | |
| project.funder.name | Fundação para a Ciência e a Tecnologia | |
| project.funder.name | Fundação para a Ciência e a Tecnologia | |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | article | pt_PT |
| relation.isAuthorOfPublication | 304abd7f-071b-4447-a8a3-4aa5f0547141 | |
| relation.isAuthorOfPublication | 86da944c-5e6a-4ec5-a56e-4ed82ece7a17 | |
| relation.isAuthorOfPublication.latestForDiscovery | 304abd7f-071b-4447-a8a3-4aa5f0547141 | |
| relation.isProjectOfPublication | 71376ce5-3732-4d41-b053-3dad707d6191 | |
| relation.isProjectOfPublication | 7027027e-87f3-442e-9bdc-9fadad40a229 | |
| relation.isProjectOfPublication | bf46abe9-5239-4806-bae6-16c7d1595d4d | |
| relation.isProjectOfPublication.latestForDiscovery | 7027027e-87f3-442e-9bdc-9fadad40a229 |